Professor, Medicine, Case Western Reserve University School of Medicine
Hematology
Dr. Stanton L. Gerson, MD
|
|
Give Review
Stanton L. Gerson, MD is an expert in the field of Hematology. He went to Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Northern Ohio Live", "Elected Member" and "Top MD". Doctor Stanton L. Gerson, MD is also published. He has 60 publications published. The lastest publication: "Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.' He accepts Medicare.
Publications
- Dual institution experience of extranodal marginal zone Lymphoma reveals excellent long-term outcomes.
- Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: ExCellent Outcomes Even in Poor-Risk Patients.
- Cancer stem cells: targeting the roots of Cancer, seeds of metastasis, and sources of therapy resistance.
- MGMT enrichment and second gene co-expression in hematopoietic progenitor Cells using separate or dual-gene lentiviral vectors.
- Exonuclease 1 is a critical mediator of survival during DNA double strand break repair in nonquiescent hematopoietic stem and progenitor Cells.
- Bcl2 overexpression rescues the hematopoietic stem Cell defects in Ku70-deficient mice by restoration of quiescence.
- Imaging Early Stage Osteogenic Differentiation of Mesenchymal Stem Cells.
- Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem Cell differentiation.
- Two-Photon Fluorescent Imaging of Myelination in the Spinal Cord.
- Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
- Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides Type.
- An intrinsic BM hematopoietic niche occupancy defect of HSC in scid mice facilitates exogenous HSC engraftment.
- Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic Cells.
- Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts.
- Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis.
- Imaging Stem Cell-derived Persistent Foci After In Vivo Selection of Lentiviral MGMT-P140K Transduced Murine Bone Marrow Cells.
- Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory Leukemia.
- Elevated AF1q expression is a poor prognostic marker for adult Acute myeloid leukemia patients with normal cytogenetics.
- Transcriptional profiling of human mesenchymal stem Cells transduced with reporter genes for imaging.
- Imaging stem Cell implant for Cellular-based therapies.
- Identification of 6-benzylthioinosine as a myeloid Leukemia differentiation-inducing compound.
- Bone marrow-derived Cells exhibiting lung epithelial Cell characteristics are enriched in vivo using methylguanine DNA methyltransferase-mediated drug resistance.
- Targets of Small interfering RNA restriction during human immunodeficiency virus type 1 replication.
- Phase I trial of VNP40101M (Cloretazine) in children with recurrent Brain tumors: a pediatric Brain tumor consortium study.
- Synergistic actions of hematopoietic and mesenchymal stem/progenitor Cells in vascularizing bioengineered tissues.
- Bioluminescence imaging of hematopoietic stem Cell repopulation in murine models.
- Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha.
- Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem Cell transplantation outcome.
- Long-term-infected telomerase-immortalized endothelial Cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.
- Clozapine alone versus clozapine and risperidone for refractory schizophrenia.
- Targeted modulation of MGMT: clinical implications.
- Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic Cells.
- Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced Melanoma.
- Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem Cells and hematopoietic stem Cells in hematologic malignancy patients.
- DNA repair defects in stem Cell function and aging.
- High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory Lymphoma: an e...
- A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk Acute leukemia.
- Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment.
- A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
- Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell Malignancies.
- In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating Cells without pretransplant irradiation conditioning.
- Measurement of anti-Cancer agent methoxyamine in plasma by tandem mass spectrometry with on-line sample extraction.
- Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts.
- Akt helps stem Cells heal the heart.
- Repopulating defect of mismatch repair-deficient hematopoietic stem Cells.
- Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary ...
- Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine.
- Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and Secondary recipients.
- SarCNU mediates selection of P140K methylguanine-DNA-methyltransferase transduced human CD34(+) Cells in vitro.
- Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells.
- Base excision repair as a therapeutic target in colon Cancer.
- Hematologic effects of linezolid: summary of clinical experience.
- Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon Cancer.
- Clinical relevance of MGMT in the treatment of Cancer.
- Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allow...
- Cancer gene therapy: scientific basis.
- Adult bone marrow stem Cells for Cell and gene therapies: implications for greater use.
- Uracil DNA glycosylase (UNG) loss enhances DNA double strand break formation in human Cancer cells exposed to pemetrexed.
- Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart Diseases.
Schools
Harvard Medical School
Hospital Of Penn
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Northern Ohio Live
- Elected Member
- Top MD
Education
-
University of Pennsylvania Health System -
Harvard Medical School
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER | 1497771661 | |
| NPPES Provider LastName | GERSON | |
| NPPES Provider FirstName | STANTON | |
| NPPES Provider ZIPCode | 441061716 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 296.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 10.14 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497771661 |
| Last Name Of The Provider | GERSON |
| First Name Of The Provider | STANTON |
| View All |
Similar Doctors
|
Dr. Paolo F. Caimi, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Alan E. Lichtin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Donald Eicher, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Henry B. Koon Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glen H. Stevens, DO |
|
|
Dr. Mohammad Mobayed, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph C. Baar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepa Jagadeesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Galena Salem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Betty K. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|